vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and KENNAMETAL INC (KMT). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $592.6M, roughly 1.0× KENNAMETAL INC). EXELIXIS, INC. runs the higher net margin — 40.8% vs 10.3%, a 30.5% gap on every dollar of revenue. On growth, KENNAMETAL INC posted the faster year-over-year revenue change (21.8% vs 5.6%). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 4.4%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Kennametal, Inc. is a manufacturer of high-performance cutting tools and engineered components used in the aerospace, defense, transportation and oil and gas drilling industries. Its customer base is global.
EXEL vs KMT — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $592.6M |
| Net Profit | $244.5M | $61.1M |
| Gross Margin | 95.6% | 35.1% |
| Operating Margin | 39.3% | 13.4% |
| Net Margin | 40.8% | 10.3% |
| Revenue YoY | 5.6% | 21.8% |
| Net Profit YoY | 74.8% | 85.0% |
| EPS (diluted) | $0.89 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | $592.6M | ||
| Q4 25 | $597.8M | $529.5M | ||
| Q3 25 | $568.3M | $498.0M | ||
| Q2 25 | $555.4M | $516.4M | ||
| Q1 25 | $566.8M | $486.4M | ||
| Q4 24 | — | $482.1M | ||
| Q3 24 | $539.5M | $481.9M | ||
| Q2 24 | $637.2M | $543.3M |
| Q1 26 | $244.5M | $61.1M | ||
| Q4 25 | $193.6M | $33.9M | ||
| Q3 25 | $184.8M | $23.3M | ||
| Q2 25 | $159.6M | $21.6M | ||
| Q1 25 | $139.9M | $31.5M | ||
| Q4 24 | — | $17.9M | ||
| Q3 24 | $118.0M | $22.1M | ||
| Q2 24 | $226.1M | $37.2M |
| Q1 26 | 95.6% | 35.1% | ||
| Q4 25 | 96.9% | 32.8% | ||
| Q3 25 | 96.6% | 31.0% | ||
| Q2 25 | 96.5% | 28.2% | ||
| Q1 25 | 96.5% | 32.1% | ||
| Q4 24 | — | 30.1% | ||
| Q3 24 | 96.8% | 31.3% | ||
| Q2 24 | 97.2% | 31.5% |
| Q1 26 | 39.3% | 13.4% | ||
| Q4 25 | 39.6% | 9.9% | ||
| Q3 25 | 37.6% | 7.5% | ||
| Q2 25 | 33.6% | 6.1% | ||
| Q1 25 | 28.8% | 9.1% | ||
| Q4 24 | — | 6.6% | ||
| Q3 24 | 25.2% | 7.5% | ||
| Q2 24 | 43.3% | 11.3% |
| Q1 26 | 40.8% | 10.3% | ||
| Q4 25 | 32.4% | 6.4% | ||
| Q3 25 | 32.5% | 4.7% | ||
| Q2 25 | 28.7% | 4.2% | ||
| Q1 25 | 24.7% | 6.5% | ||
| Q4 24 | — | 3.7% | ||
| Q3 24 | 21.9% | 4.6% | ||
| Q2 24 | 35.5% | 6.8% |
| Q1 26 | $0.89 | $0.75 | ||
| Q4 25 | $0.69 | $0.44 | ||
| Q3 25 | $0.65 | $0.30 | ||
| Q2 25 | $0.55 | $0.28 | ||
| Q1 25 | $0.47 | $0.41 | ||
| Q4 24 | — | $0.23 | ||
| Q3 24 | $0.40 | $0.28 | ||
| Q2 24 | $0.77 | $0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $106.8M |
| Total DebtLower is stronger | — | $597.4M |
| Stockholders' EquityBook value | $2.2B | — |
| Total Assets | $2.8B | $2.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | $106.8M | ||
| Q4 25 | $988.5M | $129.3M | ||
| Q3 25 | $791.1M | $103.5M | ||
| Q2 25 | $1.0B | $140.5M | ||
| Q1 25 | $1.1B | $97.5M | ||
| Q4 24 | — | $121.2M | ||
| Q3 24 | $1.2B | $119.6M | ||
| Q2 24 | $1.0B | $128.0M |
| Q1 26 | — | $597.4M | ||
| Q4 25 | — | $597.2M | ||
| Q3 25 | — | $597.0M | ||
| Q2 25 | — | $596.8M | ||
| Q1 25 | — | $596.6M | ||
| Q4 24 | — | $596.4M | ||
| Q3 24 | — | $596.2M | ||
| Q2 24 | — | $596.0M |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $1.3B | ||
| Q3 25 | $2.0B | $1.3B | ||
| Q2 25 | $2.1B | $1.3B | ||
| Q1 25 | $2.2B | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $2.3B | $1.3B | ||
| Q2 24 | $2.1B | $1.2B |
| Q1 26 | $2.8B | $2.7B | ||
| Q4 25 | $2.8B | $2.6B | ||
| Q3 25 | $2.7B | $2.5B | ||
| Q2 25 | $2.8B | $2.5B | ||
| Q1 25 | $2.9B | $2.5B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | $3.0B | $2.5B | ||
| Q2 24 | $2.8B | $2.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.45× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.46× | ||
| Q1 25 | — | 0.48× | ||
| Q4 24 | — | 0.49× | ||
| Q3 24 | — | 0.47× | ||
| Q2 24 | — | 0.48× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | — |
| Free Cash FlowOCF − Capex | $332.4M | — |
| FCF MarginFCF / Revenue | 55.5% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 1.36× | — |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $55.1M | ||
| Q3 25 | $49.0M | $17.5M | ||
| Q2 25 | $211.4M | $78.6M | ||
| Q1 25 | $240.3M | $28.8M | ||
| Q4 24 | — | $55.2M | ||
| Q3 24 | $271.3M | $45.7M | ||
| Q2 24 | $119.5M | $113.6M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $42.4M | ||
| Q3 25 | $46.2M | $-5.5M | ||
| Q2 25 | $208.5M | $57.1M | ||
| Q1 25 | $236.3M | $5.3M | ||
| Q4 24 | — | $35.9M | ||
| Q3 24 | $263.1M | $21.0M | ||
| Q2 24 | $113.0M | $90.3M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | 8.0% | ||
| Q3 25 | 8.1% | -1.1% | ||
| Q2 25 | 37.5% | 11.1% | ||
| Q1 25 | 41.7% | 1.1% | ||
| Q4 24 | — | 7.5% | ||
| Q3 24 | 48.8% | 4.4% | ||
| Q2 24 | 17.7% | 16.6% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 2.4% | ||
| Q3 25 | 0.5% | 4.6% | ||
| Q2 25 | 0.5% | 4.2% | ||
| Q1 25 | 0.7% | 4.8% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | 1.5% | 5.1% | ||
| Q2 24 | 1.0% | 4.3% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 1.63× | ||
| Q3 25 | 0.27× | 0.75× | ||
| Q2 25 | 1.32× | 3.64× | ||
| Q1 25 | 1.72× | 0.92× | ||
| Q4 24 | — | 3.08× | ||
| Q3 24 | 2.30× | 2.07× | ||
| Q2 24 | 0.53× | 3.06× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
KMT
| Americas | $298.3M | 50% |
| EMEA | $174.0M | 29% |
| Asia Pacific | $120.3M | 20% |
